Merck’s Welireg receives European approval for two indications

WELIREG is the first and only oral hypoxia-inducible factor-2 alpha inhibitor approved in the European Union

EyeQ upgrades eye care facility in Surat

Theatre (OTs) dedicated to cataract, LASIK, and retina treatments added to meet the growing demand

Health Minister inaugurates Second AIIMS Oncology Conclave at NCI-AIIMS, Jhajjar

Dr. Prabhavathi. R joins HEJJE

Dr. Prabhavathi brings over 14 years of unparalleled experience in pediatrics and a specialized focus on neurodevelopmental disorders

Sanofi updates on extraintestinal pathogenic E. coli vaccine phase 3 clinical study

No safety signals related to the vaccine candidate were identified

Nectar Life Care launches affordable anti-diabetic range of medicines

Offers affordable, high-quality solutions for diabetes care

Imfinzi perioperative regimen improved survival across muscle-invasive bladder cancer patients

Imfinzi reduced the risk of distant metastases and death from bladder cancer vs. neoadjuvant chemotherapy alone

Bristol Myers Squibb Provides Update on Phase 3 RELATIVITY-098 Trial

The safety profile of Opdualag observed in this analysis was consistent with the known profiles of nivolumab and relatlimab

Bayer files for approval of finerenone in heart failure in Japan

Finerenone is the first drug targeting the mineralocorticoid receptor (MR) pathway to demonstrate cardiovascular benefits in a Phase III study in patients with heart failure

FDA approves Roche’s Evrysdi tablet as first and only tablet for Spinal Muscular Atrophy

Evrysdi is the only non-invasive disease-modifying SMA treatment and is approved in over 100 countries